Gelteq Ltd
GELS evidence brief
What we can confirm
- Market Cap:
- $7.5M
What it means
What to watch
Prepared research question
What matters most for GELS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GELS
Gelteq Ltd is an early-stage drug delivery company developing a proprietary gel-based technology platform for pharmaceutical, nutraceutical, and OTC products, currently prioritizing a 505(b)(2) regulatory pathway and out-licensing strategy.
Key risk: History of losses
Market Cap
$7.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Gelteq Ltd is an early-stage drug delivery company developing a proprietary gel-based technology platform for pharmaceutical, nutraceutical, and OTC products, currently prioritizing a 505(b)(2) regulatory pathway and out-licensing strategy.
- Gelteq incurred total losses of approximately AUD$6,645,453 and AUD$3,546,195 in fiscal years ended June 30, 2025 and 2024, respectively [sec · filed 2025-11-17].
- The company is prioritizing a 505(b)(2) regulatory pathway for an off-patent API, with an estimated 12-15 month timeline including lab testing and clinical trials [sec · filed 2025-11-17].
- Gelteq has completed dissolution studies for a gel-based OTC product candidate and plans to conduct bioequivalence and safety studies for FDA approval [sec · filed 2025-11-17].
- The company expects to continue incurring losses for the foreseeable future and will require substantial additional financing to achieve its goals [sec · filed 2025-11-17].
- Gelteq entered into a rental contract for laboratory facilities with Monash University on February 2, 2024, extended to February 2, 2026 [sec · filed 2025-11-17].
What works
- Gelteq's gel delivery technology is being tested with multiple APIs, including dysphagia-based APIs where the company sees the greatest unmet need [sec · filed 2024-11-15].
- The company has completed dissolution studies for an OTC product candidate, allowing future clinical data to be compared to an existing FDA-approved product [sec · filed 2025-11-17].
- Gelteq is pursuing a 505(b)(2) pathway, which can potentially shorten development time by relying on existing safety and efficacy data [sec · filed 2025-11-17].
What to weigh
- Gelteq is an early-stage company with a history of losses and no assurance of achieving profitability or successful product commercialization [sec · filed 2025-11-17].
- The company operates in highly regulated and competitive markets, and regulatory approval and market acceptance of its products are uncertain [sec · filed 2025-11-17].
- Gelteq will require substantial additional financing to fund its development and commercialization efforts, and failure to obtain capital could force delays or termination of activities [sec · filed 2025-11-17].
- Clinical trials may take longer and be more costly than budgeted, and results of earlier studies may not predict future trial outcomes [sec · filed 2025-11-17].
From the filings
Quoted directly from source documents.
Gelteq has incurred significant losses in recent fiscal years.
“We incurred total losses in the past of approximately AUD$6,645,453 and AUD$3,546,195 in the fiscal years ended June 30, 2025 and 2024 respectively.”
SEC filings · November 17, 2025
The company is pursuing a 505(b)(2) pathway for an off-patent API.
“With one of these off-patent APIs we are entering into the 505(b)(2) pathway, which has the potential to allow us to add a prescription product to our product portfolio that uses our gel base.”
SEC filings · November 15, 2024
The company has completed dissolution studies for an OTC product candidate.
“For this API candidate, we have completed dissolution comparisons to existing market products so that our future clinical data can be compared in bioequivalence studies to an existing, FDA approved product containing the same API.”
SEC filings · November 17, 2025
Risks & what to watch (4)›
Key risks
- History of losses — Gelteq has incurred significant losses (AUD$6.6M in FY2025) and expects losses to continue [sec · filed 2025-11-17].
- Need for additional capital — The company requires substantial financing to fund R&D and commercialization; failure to obtain capital could force delays [sec · filed 2025-11-17].
- Regulatory and market uncertainty — Products are in early development; regulatory approval and market acceptance are uncertain in competitive markets [sec · filed 2025-11-17].
- Clinical trial risks — Trials may take longer and cost more than budgeted; earlier results may not predict future outcomes [sec · filed 2025-11-17].
What to watch
- Progress and results of the two pre-clinical trials (one in Melbourne, Australia and one in India) [sec · filed 2025-11-17].
- Initiation and outcomes of bioequivalence and safety studies required for FDA approval of the OTC product candidate [sec · filed 2025-11-17].
- Ability to secure additional financing or a collaboration agreement to fund ongoing operations and development [sec · filed 2025-11-17].
- Execution of the 505(b)(2) pathway timeline (estimated 12-15 months) for a prescription product [sec · filed 2025-11-17].
Sources: SEC filings · Generated September 10, 2026 · How we verify sources →
Run Gelteq Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gelteq Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$28K
| Holder | Shares | Value |
|---|---|---|
| private advisor group, llc | 16,668 | $11K |
| citadel advisors llc | 13,830 | $9K |
| two sigma investments, lp | 10,052 | $7K |
| ubs group ag | 1,834 | $1K |
| wedbush securities inc | 20,000 | $13 |
Short Interest
as of May 21, 2026- % of float
- 0.5%
- Days to cover
- 1.6
- Shares short
- 37,312
- Daily short volume (Oct 9, 2026)
- 13.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GELS short interestFrequently asked questions
What is the AI investment thesis for Gelteq Ltd?
Gelteq Ltd is an early-stage drug delivery company developing a proprietary gel-based technology platform for pharmaceutical, nutraceutical, and OTC products, currently prioritizing a 505(b)(2) regulatory pathway and out-licensing strategy.
Who is the CEO of Gelteq Ltd?
Mr. Nathan Jacob Givoni is the chief executive officer of Gelteq Ltd (GELS).
Where is Gelteq Ltd headquartered?
Gelteq Ltd (GELS) is headquartered in Clayton, VIC, Australia.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.